A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Maintenance of Efficacy of Ecopipam in Children, Adolescents and Adults With Tourette's Disorder
Latest Information Update: 08 May 2025
At a glance
- Drugs Ecopipam (Primary)
- Indications Gilles de la Tourette's syndrome
- Focus Registrational; Therapeutic Use
- Acronyms D1AMOND
- Sponsors Emalex Biosciences
Most Recent Events
- 22 Apr 2025 Status changed from active, no longer recruiting to completed.
- 25 Feb 2025 According to a Emalex Biosciences media release, Primary endpoint (Yale Global Tic Severity Scale (YGTSS)) has been met.
- 25 Feb 2025 Results published in the Emalex Biosciences media release